Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?-Reference-Cited by-同舟云学术

Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?

Published:2015-12-02 Issue:4 Volume:15 Page:509-517
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Whitehead Stephen S.

Funder

National Institutes of Health

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

http://www.tandfonline.com/doi/pdf/10.1586/14760584.2016.1115727

Reference27 articles.

1. Production of Immunity to Dengue with Virus Modified by Propagation in Mice

2. A Prospective Study of Dengue Infections in Bangkok

3. Antibody-Enhanced Infection of Monocytes as the Pathogenetic Mechanism for Severe Dengue Illness

4. Neutralization and Antibody-Dependent Enhancement of Dengue Viruses

5. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dengue vaccine endgame: why has the global response to exponential demand in the tropics been so slow?;Frontiers in Tropical Diseases;2024-09-09

2. Flavivirus cross-reactivity: Insights into e-protein conservancy, pre-existing immunity, and co-infection;The Microbe;2024-09

3. An effective pan-serotype dengue vaccine and enhanced control strategies could help in reducing the severe dengue burden in Bangladesh–A perspective;Frontiers in Microbiology;2024-08-20

4. Edging towards a third dengue vaccine;The Lancet Infectious Diseases;2024-08

5. Approaches of dengue control: vaccine strategies and future aspects;Frontiers in Immunology;2024-02-29